help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walker, L. C.
Right arrow Articles by Sorscher, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, L. C.
Right arrow Articles by Sorscher, E. J.

Am. J. Respir. Crit. Care Med., Vol 155, No. 5, May 1997, 1684-1689.

Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR

LC Walker, CJ Venglarik, G Aubin, MR Weatherly, NA McCarty, B Lesnick, F Ruiz, JP Clancy and EJ Sorscher
Department of Pediatrics, Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 35294-0005, USA.

Patients with cystic fibrosis (CF) display defects in airway ion transport, but the influence of airway transport phenotype on improved prognosis is not known. We studied airway bioelectric properties in five CF patients with the rare A455E mutation that is associated with mild pulmonary disease. We also evaluated five patients possessing premature truncation mutations (G542X and R553X) for which an association with mild pulmonary disease has not been as well established. We found no evidence in vivo that a mild lung disease mutation in the CF transmembrane regulator gene (CFTR) led to correction or partial correction of: (1) unstimulated Cl- secretion; (2) beta-agonist-activated Cl- secretion; (3) basal sodium reabsorption; or (4) amiloride-sensitive airway sodium transport. Early phase therapeutic trials in CF, including human gene transfer trials, rely heavily on improvements in airway potential difference to identify promising interventions and an improved prognosis. Based on our findings in a naturally occurring group of CF patients with an improved pulmonary prognosis (A455E), one can argue that marked clinical benefit might be possible without any improvement whatsoever in airway bioelectric phenotype. Moreover, if genetic modifiers exist that influence the severity of a particular CFTR mutation (e.g., A455E), these may be independent of human airway Cl-secretion in vivo, since we detected minimal Cl--secretory responses in patients with A455E.


This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
S. M. Rowe, F. Accurso, and J. P. Clancy
Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials
Proceedings of the ATS, August 1, 2007; 4(4): 387 - 398.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
P G Noone and K W Southern
Unravelling salt transport in cystic fibrosis
Thorax, November 1, 2004; 59(11): 916 - 917.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. L. Wallace, P. M. Barker, and K. W. Southern
Nasal Airway Ion Transport and Lung Function in Young People with Cystic Fibrosis
Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 594 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. P. Naren, B. Cobb, C. Li, K. Roy, D. Nelson, G. D. Heda, J. Liao, K. L. Kirk, E. J. Sorscher, J. Hanrahan, et al.
A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA
PNAS, January 7, 2003; 100(1): 342 - 346.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Schibler, I. Bolt, S. Gallati, M.H. Schoni, and R. Kraemer
High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and {Delta}F508
Eur. Respir. J., June 1, 2001; 17(6): 1181 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Wilschanski, H. Famini, N. Strauss-Liviatan, J. Rivlin, H. Blau, H. Bibi, L. Bentur, Y. Yahav, H. Springer, M.R. Kramer, et al.
Nasal potential difference measurements in patients with atypical cystic fibrosis
Eur. Respir. J., June 1, 2001; 17(6): 1208 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. P. CLANCY, Z. BEBOK, F. RUIZ, C. KING, J. JONES, L. WALKER, H. GREER, J. HONG, L. WING, M. MACALUSO, et al.
Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis
Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1683 - 1692.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. WILSCHANSKI, C. FAMINI, H. BLAU, J. RIVLIN, A. AUGARTEN, A. AVITAL, B. KEREM, and E. KEREM
A Pilot Study of the Effect of Gentamicin on Nasal Potential Difference Measurements in Cystic Fibrosis Patients Carrying Stop Mutations
Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): 860 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
J. M. PILEWSKI and R. A. FRIZZELL
Role of CFTR in Airway Disease
Physiol Rev, January 1, 1999; 79(1): 215 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. C. RUBENSTEIN and P. L. ZEITLIN
A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in Delta F508-Homozygous Cystic Fibrosis Patients . Partial Restoration of Nasal Epithelial CFTR Function
Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 484 - 490.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society